Patents by Inventor Maxwell David Cummings

Maxwell David Cummings has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS
    Publication number: 20220315557
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.
    Type: Application
    Filed: November 25, 2020
    Publication date: October 6, 2022
    Inventors: Tianbao LU, Brett Douglas Allison, Joseph Kent Barbay, Peter J. Connolly, Maxwell David Cummings, Gaston Diels, James Patrick Edwards, Kevin D. Kreutter, Ulrike Philippar, Fang Shen, Johannes Wilhelmus John Fitzgerald Thuring, Tongfei Wu, Didier Jean-Claude Berthelot
  • Pyrazole derivatives as MALT1 inhibitors
    Patent number: 11040031
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, and G, are defined herein.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: June 22, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tianbao Lu, Peter J. Connolly, Maxwell David Cummings, Joseph Kent Barbay, Kevin D. Kreutter, Tongfei Wu, Gaston Stanislas Marcella Diels, Jan Willem Thuring, Ulrike Philippar, James Patrick Edwards, Fang Shen
  • Pyrazole derivatives as MALT1 inhibitors
    Patent number: 10954214
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 23, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tianbao Lu, Brett Douglas Allison, Joseph Kent Barbay, Peter J. Connolly, Maxwell David Cummings, Gaston Diels, James Patrick Edwards, Kevin D. Kreutter, Ulrike Philippar, Fang Shen, Johannes Wilhelmus John Fitzgerald Thuring, Tongfei Wu, Didier Jean-Claude Berthelot
  • Pyrazole derivatives as MALT1 inhibitors
    Patent number: 10888550
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R7, G1 and G2, are defined herein.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: January 12, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tianbao Lu, Peter J. Connolly, Maxwell David Cummings, Gaston Stanislas Marcella Diels, Jan Willem Thuring, Ulrike Philippar, James Patrick Edwards, Didier Jean-Claude Berthelot, Tongfei Wu
  • PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS
    Publication number: 20190381012
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R7, G1 and G2, are defined herein.
    Type: Application
    Filed: June 13, 2019
    Publication date: December 19, 2019
    Inventors: Tianbao LU, Peter J. CONNOLLY, Maxwell David CUMMINGS, Gaston Stanislas Marcella DIELS, Jan Willem THURING, Ulrike PHILIPPAR, James Patrick EDWARDS, Didier Jean-Claude BERTHELOT, Tongfei WU
  • PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS
    Publication number: 20190381019
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT 1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, and G, are defined herein.
    Type: Application
    Filed: June 13, 2019
    Publication date: December 19, 2019
    Inventors: Tianbao Lu, Peter J. Connolly, Maxwell David Cummings, Joseph Kent Barbay, Kevin D. Kreutter, Tongfei Wu, Gaston Stanislas Marcella Diels, Jan Willem Thuring, Ulrike Philippar, James Patrick Edwards, Fang Shen
  • PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS
    Publication number: 20180170909
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.
    Type: Application
    Filed: December 20, 2017
    Publication date: June 21, 2018
    Inventors: Tianbao Lu, Brett Douglas Allison, Joseph Kent Barbay, Peter J. Connolly, Maxwell David Cummings, Gaston Diels, James Patrick Edwards, Kevin D. Kreutter, Ulrike Philippar, Fang Shen, Johannes Wilhelmus John Fitzgerald Thuring, Tongfei Wu
  • Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions
    Patent number: 7868023
    Abstract: Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. The compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein Ra, Rb, and Rc are as defined in the specification, as are A Z, Q, R1 and R2.
    Type: Grant
    Filed: April 3, 2008
    Date of Patent: January 11, 2011
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nalin L. Subasinghe, Shelley Ballentine, Jeremy M. Travins, Ehab M. Khalil, Farah Ali, Kristi A. Leonard, Joan M. Gushue, Michael Peter Winters, Heather Hufnagel, Maxwell David Cummings
  • NOVEL THIOPHENE SULFOXIMINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS
    Publication number: 20080255108
    Abstract: Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. Said compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein Ra, Rb, and Rc are defined in the specification, as are A Z, Q, R1 and R2.
    Type: Application
    Filed: April 3, 2008
    Publication date: October 16, 2008
    Inventors: Nalin L. Subasinghe, Shelley Ballentine, Jeremy M. Travins, Ehab M. Khalil, Farah Ali, Kristi A. Leonard, Joan M. Gushue, Michael Peter Winters, Heather Hufnagel, Maxwell David Cummings
  • Protease inhibitors
    Patent number: 7405209
    Abstract: The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: July 29, 2008
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Robert Wells Marquis, Jr., Yu Ru, Daniel Frank Veber, Maxwell David Cummings, Scott Kevin Thompson, Dennis Shinji Yamashita
  • Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions
    Patent number: 7385066
    Abstract: Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. The compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein Ra, Rb, and Rc are defined in the specification, as are A Z, Q, R1 and R2.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: June 10, 2008
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Nalin L. Subasinghe, Shelley Ballentine, Jeremy M. Travins, Ehab M. Khalil, Farah Ali, Kristi A. Leonard, Joan M. Gushue, Michael Peter Winters, Heather Hufnagel, Maxwell David Cummings
  • Substituted 1,4-diazepines and uses thereof
    Patent number: 7115598
    Abstract: The present invention is directed to novel 1,4-diazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions.
    Type: Grant
    Filed: April 21, 2004
    Date of Patent: October 3, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Tianbao Lu, Karen L. Milkiewicz, Pierre Raboisson, Maxwell David Cummings, Raul R. Calvo, Daniel J. Parks, Louis V. Lafrance, III, Juan Jose Marugan Sanchez, Joan Gushue, Kristi Leonard
  • Peptide deformylase inhibitors
    Patent number: 7115605
    Abstract: PDF inhibitors and novel methods for their use are provided.
    Type: Grant
    Filed: April 5, 2004
    Date of Patent: October 3, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: Kelly M. Aubart, Siegfried B. Christensen, IV, Jacques Briand, Maxwell David Cummings
  • Substituted 1,4-diazepines and uses thereof
    Publication number: 20040220179
    Abstract: The present invention is directed to novel 1,4-diazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions.
    Type: Application
    Filed: April 21, 2004
    Publication date: November 4, 2004
    Inventors: Tianbao Lu, Karen L. Milkiewicz, Pierre Raboisson, Maxwell David Cummings, Raul R. Calvo, Daniel J. Parks, Louis V. Lafrance, Juan Jose Marugan Sanchez, Joan Gushue, Kristi Leonard
  • Peptide deformylase inhibitors
    Patent number: 6806369
    Abstract: PDF inhibitors and novel methods for their use are provided.
    Type: Grant
    Filed: November 5, 2002
    Date of Patent: October 19, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Kelly M. Aubart, Siegfried B. Christensen, IV, Jacques Briand, Maxwell David Cummings
  • Peptide deformylase inhibitors
    Publication number: 20040192719
    Abstract: PDF inhibitors and novel methods for their use are provided.
    Type: Application
    Filed: April 5, 2004
    Publication date: September 30, 2004
    Applicant: SmithKline Beecham Corporation
    Inventors: Kelly M. Aubart, Siegfried B. Christensen, Jacques Briand, Maxwell David Cummings
  • Peptide deformylase inhibtors
    Publication number: 20040053932
    Abstract: The present invention involves novel anti-bacterial compounds represented by Formula (I) hereinbelow and their use as PDF inhibitors.
    Type: Application
    Filed: November 5, 2002
    Publication date: March 18, 2004
    Inventors: Kelly M. Aubart, Siegfried B. Christensen IV, Jacques Briand, Maxwell David Cummings
  • Peptide deformylase inhibitors
    Publication number: 20040034024
    Abstract: PDF inhibitors and novel methods for their use are provided.
    Type: Application
    Filed: November 5, 2002
    Publication date: February 19, 2004
    Inventors: Kelly M Aubart, Siegfried B Christensen, Jacques Briand, Maxwell David Cummings
  • Protease inhibitors
    Publication number: 20040002487
    Abstract: The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
    Type: Application
    Filed: April 1, 2003
    Publication date: January 1, 2004
    Inventors: Robert Wells Marquis, Yu Ru, Daniel Frank Veber, Maxwell David Cummings, Scott Kevin Thompson, Dennis Shinji Yamashita
  • Protease inhibitors
    Publication number: 20030225061
    Abstract: The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
    Type: Application
    Filed: April 1, 2003
    Publication date: December 4, 2003
    Inventors: Robert Wells Marquis, Yu Ru, Daniel Frank Veber, Maxwell David Cummings, Scott Kevin Thompson, Dennis Shinji Yamashita